Corporate Banner
Satellite Banner
Technology Networks Header
Friday, September 19, 2014
Technology Networks
 
Register | Sign in
Home Page > Videos > Extracorporeal Elimination of Circulating Exosomes as a Therapeutic Adjunct to Address Infectious Disease and Cancer
  Videos

Return

Extracorporeal Elimination of Circulating Exosomes as a Therapeutic Adjunct to Address Infectious Disease and Cancer
SelectBio

The Aethlon Hemopurifier® is a first-in-class device that targets the rapid elimination of infectious disease and cancer glycopathogens from circulation. In cancer, the Hemopurifier has been demonstrated to capture exosomes underlying lymphoma, melanoma, ovarian, and breast cancer. These microvesicular particles trigger apoptosis of immune cells and have been reported to facilitate tumor growth, metastasis, and the development of drug resistance. In design, the Hemopurifier consists of the affinity lectin Galanthus nivalis agglutinin (GNA) immobilized in the outer-capillary space of plasma membrane technologies. The resulting mechanism provides selective target elimination as GNA binds high mannose signatures abundant on the surface of exosomes and viral glycoproteins. Studies of hepatitis c (HCV) infected patients receiving a three-treatment Hemopurifier protocol combined with interferon-based standard of care resulted in undetectable HCV in as little as seven days in hard-to-treat genotype-1 patients. The studies also documented the ability of the Hemopurifier to capture as many as 300 billion HCV copies during a single six- hour treatment. The FDA recently approved an IDE that allows for the initiation of US feasibility studies.

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
Blood Cleanser for Sepsis
Dialysis-like ‘biospleen’ quickly filters bacteria, fungi and toxins.
Intestinal Bacteria Needed for Strong Flu Vaccine Responses in Mice
Study demonstrate a dependency on gut bacteria for strong immune responses to the seasonal flu and inactivated polio vaccines.
Blocking One Receptor on Cells Could Halt Rheumatoid Arthritis
Researchers uncovered multiple pathological processes driven by the activation of the receptor.
New Defence Mechanism Against Viruses Discovered
Mechanism may represent one of the oldest defence mechanisms against viruses in evolutionary history.
Novel Immunotherapy Breast Cancer Vaccine
Vaccine Decreases Recurrence in HER2 Positive Breast Cancer Patients.
Cell ‘Memory’ Could be Key to Strengthen Vaccine Efficacy
Virginia Tech Carilion Research Institute scientists uncover immune system secret.
Apitope Treatment Approach Published in Nature Communications
Scientists discover how to 'switch off' autoimmune diseases.
NIH-Led Scientists Discover HIV Antibody that Binds to Novel Target on Virus
The antibody, 35O22, prevents 62 percent of known HIV strains from infecting cells in the laboratory.
Breakthrough Melanoma Treatment, Keytruda, Developed
New immunotherapy launched in the US for treatment of adults with advanced melanoma, developed using antibody humanization expertise at UK’s MRC Technology.
‘Switching off’ Autoimmune Diseases
Scientists have made an important breakthrough in the fight against debilitating autoimmune diseases by revealing how to stop cells attacking healthy body tissue.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv